Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.455 USD | -1.41% | +1.22% | -39.24% |
02/05 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
29/02 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.24% | 330M | |
+20.79% | 47.9B | |
+46.56% | 41.42B | |
-2.61% | 40.7B | |
-6.20% | 28.92B | |
+10.21% | 25.55B | |
-21.83% | 19.27B | |
-2.00% | 12.15B | |
+30.77% | 12.14B | |
-0.82% | 11.99B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Sector Update: Health Care Stocks Flat Ahead of Thursday's Market Open